GreyBird Ventures is a Concord, Massachusetts-based venture capital firm founded in 2016, focused on early-stage healthcare investments, particularly in diagnostics and precision medicine. The firm typically invests from Seed to Series A, backing companies that improve clinical decision-making and enable more precise treatment selection.

GreyBird’s thesis centers on technologies that strengthen the “front end” of medicine, including diagnostics, biomarkers, and data-driven tools that match patients to the right therapies. It is a highly focused, thesis-driven investor with deep domain expertise, often backing platform technologies that combine biological insight with data and analytics. The team brings significant operating and industry experience, particularly in medtech and healthcare systems.

The firm primarily invests in the United States, with selective international exposure. For neurotechnology, GreyBird is most relevant for companies working in neurodiagnostics, digital biomarkers, and precision psychiatry, rather than implantable devices or broad therapeutics. It stands out as a strong fit for businesses using data and diagnostics to improve neurological care pathways and patient stratification.